Added to YB: 2025-01-07
Pitch date: 2024-11-20
CAMP [bearish]
Camp4 Therapeutics Corporation
+26.67%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
Market Cap
$231.6M
Pitch Price
$6.00
Price Target
0.50 (-89%)
Dividend
N/A
EV/EBITDA
-2.89
P/E
-2.05
EV/Sales
34.19
Sector
Biotechnology
Category
N/A
Show full summary:
CAMP4 THERAPEUTICS CORPORATION - $CAMP
CAMP short: Pre-revenue biotech IPO targeting rare UCDs. RFK Jr. as potential HHS head poses regulatory risk for mRNA/gene therapies. FDA reform could halt approvals. Limited upside, 90%+ downside. Catalysts: post-IPO selling, political actions against gene therapy sector.
Read full article (6 min)